[HTML][HTML] Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients
Though an important cause of morbidity and mortality in solid organ transplantation (SOT),
the long-term outcomes of cytomegalovirus (CMV) disease treatment have not been well …
the long-term outcomes of cytomegalovirus (CMV) disease treatment have not been well …
[HTML][HTML] Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
C Paya, A Humar, ED Dominguez, K Washburn… - American Journal of …, 2004 - Elsevier
We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …
[HTML][HTML] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ
transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized …
transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized …
Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir
J Fellay, JP Venetz, JD Aubert, C Seydoux… - Transplantation …, 2005 - Elsevier
Valganciclovir (VGC) has proved efficacious and safe for the prophylaxis against
cytomegalovirus (CMV) in high-risk transplant recipients and for the treatment of CMV …
cytomegalovirus (CMV) in high-risk transplant recipients and for the treatment of CMV …
A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients
A Humar, D Siegal, G Moussa… - The Journal of infectious …, 2005 - academic.oup.com
We assessed valganciclovir for the treatment of cytomegalovirus (CMV) in organ-transplant
recipients. Virologic and clinical outcomes were compared with those in matched historical …
recipients. Virologic and clinical outcomes were compared with those in matched historical …
New developments in the management of cytomegalovirus infection after solid organ transplantation
AJ Eid, RR Razonable - Drugs, 2010 - Springer
Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …
management, cytomegalovirus (CMV) remains one of the most important pathogens …
Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients
E Mylonakis, WM Kallas… - Clinical infectious …, 2002 - academic.oup.com
The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and
disease progression. The clinical significance of such resistance in solid-organ …
disease progression. The clinical significance of such resistance in solid-organ …
Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients
MA Harbison, PC De Girolami, RL Jenkins… - …, 1988 - journals.lww.com
The clinical and virologic efficacy of ganciclovir (9-[1, 3-dihydroxy-2-propoxymethyl]
guanine) in the treatment of severe CMV infections in solid organ transplant recipients was …
guanine) in the treatment of severe CMV infections in solid organ transplant recipients was …
Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir
DL Dunn, JL Mayoral, KJ Gillingham, CM Loeffler… - …, 1991 - journals.lww.com
The occurrence of cytomegalovirus infection after solid organ transplantation has been
correlated with decreased patient and allograft survival. The disease has not been …
correlated with decreased patient and allograft survival. The disease has not been …
Prevention dof recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir
N Turgeon, JA Fishman, M Doran… - Transplant Infectious …, 2000 - Wiley Online Library
Background: Although the primary treatment of symptomatic cytomegalovirus (CMV) disease
in organ transplant recipients is successful in> 90% of individuals, relapsing disease …
in organ transplant recipients is successful in> 90% of individuals, relapsing disease …
相关搜索
- transplant recipients cytomegalovirus infection
- transplant recipients valganciclovir for the treatment
- transplant recipients oral ganciclovir
- intravenous ganciclovir oral valganciclovir
- intravenous ganciclovir cytomegalovirus disease
- oral valganciclovir cytomegalovirus disease
- valganciclovir for the treatment cytomegalovirus infection
- valganciclovir for the treatment prospective assessment
- transplant recipients prospective assessment
- transplant recipients antiviral therapy
- transplant recipients cytomegalovirus disease
- transplant recipients ganciclovir therapy
- oral ganciclovir cytomegalovirus disease